Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEMA5A shRNA
- Development stage
- Preclinical
- Lead developer
- University of Nebraska Medical Center
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SEMA5A shRNA is a short hairpin RNA designed to silence the expression of semaphorin 5A (SEMA5A), a member of the semaphorin family of axon guidance molecules. In the context of pancreatic cancer research, SEMA5A has been identified as a key regulator of metastatic dissemination, influencing both epithelial-to-mesenchymal transition (EMT) at primary tumor sites and mesenchymal-to-epithelial transition (MET) at secondary metastatic sites. By utilizing shRNA-mediated knockdown, researchers have demonstrated that reducing SEMA5A levels can alter E-cadherin expression and cellular migration, thereby impacting the organ-specific homing and metastatic potential of pancreatic cancer cells. This tool is primarily used in preclinical research to investigate the molecular mechanisms of cancer progression and to evaluate SEMA5A as a potential therapeutic target.
- Other names
- semaphorin 5A short hairpin RNAsemaphorin5A short hairpin RNAsemaphorin-5A short hairpin RNAshSEMA5AshSEMA-5AshSEMA 5A
02
Targets
Semaphorin axis (Semaphorin signaling family)
Beyond the preview
Go deeper on SEMA5A shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEMA5A shRNA.